Cybin Inc. (CYBN)

Develops psychedelic therapeutics for the treatment of mental health disorders.

CYBN Stock Quote

Company Report

Cybin Inc., headquartered in Toronto, Canada, is a biopharmaceutical company specializing in the development of psychedelic-based therapeutics. The company is committed to advancing treatments that harness the potential of psychedelic compounds to address a range of mental health disorders.

At the forefront of Cybin's development pipeline is CYB003, a deuterated psilocybin analog aimed at treating major depressive disorder and alcohol use disorders. Additionally, CYB004, a deuterated dimethyltryptamine, is being developed for the treatment of anxiety disorders, while CYB005 focuses on a phenethylamine derivative targeting neuroinflammation. These innovative therapies represent Cybin's dedication to expanding treatment options for patients struggling with various psychiatric conditions.

Cybin has also pioneered EMBARK, a psychedelic-assisted psychotherapy approach designed to enhance therapeutic outcomes through the careful integration of psychedelic compounds with psychotherapeutic practices. With a robust research and development strategy, Cybin Inc. is poised to lead advancements in psychedelic medicine, striving to improve mental health outcomes globally.

CYBN EPS Chart

CYBN Revenue Chart

Stock Research

WINT NEOG HTBK GOSS SVRE NWBI PLX

CYBN Chart

View interactive chart for CYBN

CYBN Profile

CYBN News

Analyst Ratings